Dana-Farber Cancer Institute (DFCI) is seeking a Director of Operations Quality for its Hematopoietic Stem Cell Transplant (HSCT) & Immune Effector Cell Therapy Programs (IEC). This is a mission critical and highly visible operational leadership role reporting into the nationally recognized Division of Stem Cell Transplantation and Cellular Therapies at the Institute. The combined programs are among the largest in the country and serve adult and pediatric patients and families of DFCI, Brigham & Women’s Hospital, and Boston Children’s Hospital. All three institutions are Harvard Medical School (HMS) teaching affiliates.
The Director of Operations Quality for the Hematopoietic Stem Cell Transplant (HSCT) & Cellular Therapies Programs provides leadership and direction to ensure operational excellence across a broad range of activities and sites for two of the largest and most respected HSCT and Cellular Therapies programs in the U.S. Working collaboratively with faculty and staff to develop and implement strategies to achieve programmatic excellence, this position will rely on a deep understanding of clinical operations in a large and highly complex care delivery system to successfully build and socialize methods to optimize effective operations.
The Director will serve as a key leader for programmatic interests in overall operational effectiveness and innovative solutions that ensure patient safety, regulatory compliance, clinical templates, and electronic and other tools to support improvements in utilization and outcomes. The Director will also ensure the accuracy and reliability of documentation that supports clinical pathways, outcomes reporting and analytics, revenue integrity, business planning, and well-engineered day to day workflows. The Director will ensure positive and supportive interface with regulatory organizations and effective working relationships with commercial organizations to implement new products. The Director will also create and maintain programs to ensure staff readiness and training, and process improvements that support financial performance.
The Director will serve as a key consultant and provide guidance to other programmatic leads across sites of care, including inpatient and outpatient clinical operations, institutional facilities teams, clinical and cell processing laboratories, patient coordination, donor services, community-based care, referring physician relations, business analytics, financial planning and strategic planning. The Director reports to the Vice President for the HSCT & Cellular Therapies Service Line. The Director’s team of 20 staff members includes quality assurance and improvement managers and specialists, outcomes reporting and program administrators, and an audit team.
Internal Number: 2257
About Dana- Farber Cancer Institute
The DFCI is a world leader in basic and clinical research, training and application of advanced diagnostic and treatment methods in the mission of conquering cancer, HIV/AIDS and related diseases. Today DFCI employs nearly 5,000 people supporting more than 300,000 patient visits a year, is involved in some 700 clinical trials, and internationally renowned for its blending of research and clinical excellence. The Institute brings together exceptional professionals with the best technologies in a genuinely positive environment and provides compassionate and comprehensive care to children and adults. DFCI’s expertise in these areas in the fight against cancer uniquely positions it to develop and test the next generation of cancer therapies in both the laboratory and the clinic. See www.danafarber.org
BACK TO TOP
Merchant Privacy Statement Your right to privacy is important. Our organization believes that the personal information you choose to furnish online should only be used to help us provide you with the highest quality services and support. We will not share this information with any other party.
We do not share your credit card information with any outside parties.